| Project/Area Number |
16K21111
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General medical chemistry
Molecular biology
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | cancer / HRas / HRas mRNA / HRas isoform / HRas translation / cancer mutation / p14HRas / bladder cancer / IRES / synonymous mutation / gene |
|---|
| Outline of Final Research Achievements |
Ras genes are the most mutated proto-oncogenes in cancer. Here we identified a new Ras protein: p14HRas. We identified the mechanisms of regulation of p14 and investigated p14’s mutation and upregulation in cancer. We discovered the mechanism of action. We propose a new mechanism for oncogenicity in cancer involving a new proto-oncogene (p14HRas) and an alternative translation mechanism. Further studies can be aimed at targeting p14HRas or its mechanisms of expression for therapy in cancer patients.
|
| Academic Significance and Societal Importance of the Research Achievements |
Ras genes are the most mutated proto-oncogenes in cancer. We propose a new mechanism for oncogenicity in cancer involving a new HRas proto-oncogene. Further studies can be aimed at targeting p14HRas or its mechanisms of expression (also identified here) for a new therapy to treat cancer patients.
|
